H.C. Wainwright Reaffirms Their Buy Rating on Caladrius Biosciences (CLBS)

By Austin Angelo

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Caladrius Biosciences (CLBSResearch Report) today and set a price target of $18.50. The company’s shares opened today at $4.55.

Pantginis noted:

“Valuation and risks to price target achievement; only need a little to be potentially quite meaningful. We reiterage our Buy rating and $18.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. As part of our valuation projections, we make the following assumptions, which we also believe provide additional levels of conservatism to our projections.”

According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -23.1% and a 22.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

Currently, the analyst consensus on Caladrius Biosciences is a Moderate Buy with an average price target of $18.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.65 and a one-year low of $3.05. Currently, Caladrius Biosciences has an average volume of 26.89K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.